2 weeks Ago By Defense World Staff
American Century Companies Inc. boosted its stake in Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT – Free Report ) by 10.
7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,018 shares of the biotechnology company’s stock after buying an additional 4,547 shares during the quarter. American Century Companies Inc.
owned approximately 0.17% of Arcturus Therapeutics worth $798,000 as of its most recent SEC filing. A number of other institutional investors have also added to or reduced their stakes in ARCT.
Franklin Resources Inc. increased its holdings in Arcturus Therapeutics by 54.6% during the third quarter.
Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares during the last quarter. Empire Life Investments Inc.
raised its holdings in shares of Arcturus Therapeutics by 85.5% during the 4th quarter. Empire Life Investments Inc.
now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after buying an additional 128,771 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Arcturus Therapeutics by 139.
7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after buying an additional 47,824 shares during the period.
Spire Wealth Management boosted its position in Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 10,746 shares during the period.
Finally, SG Americas Securities LLC lifted its stake in Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares during the period.
94.54% of the stock is owned by institutional investors. Wall Street Analysts Forecast Growth A number of equities analysts have issued reports on the company.
BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.
00 to $68.00 and set a “buy” rating for the company in a research note on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.
00 price target on shares of Arcturus Therapeutics in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $58.
00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock.
According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $59.20. Arcturus Therapeutics Stock Up 3.
7 % NASDAQ ARCT opened at $9.70 on Friday. Arcturus Therapeutics Holdings Inc.
has a 52 week low of $8.04 and a 52 week high of $45.00.
The company has a fifty day moving average of $13.89 and a two-hundred day moving average of $16.89.
The firm has a market capitalization of $263.06 million, a price-to-earnings ratio of -4.37 and a beta of 3.
41. Arcturus Therapeutics ( NASDAQ:ARCT – Get Free Report ) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.
11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78).
Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.
The company had revenue of $22.77 million for the quarter, compared to analysts’ expectations of $44.64 million.
Equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.
Arcturus Therapeutics Company Profile ( Free Report ) Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. Featured Stories Five stocks we like better than Arcturus Therapeutics What Makes a Stock a Good Dividend Stock? JPMorgan is a Buy, if You Can Handle The Volatility How to Choose Top Rated Stocks United States Steel’s Crash: An Unmissable Buying Opportunity The Most Important Warren Buffett Stock for Investors: His Own Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT – Free Report ). Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
